Vaccine injury signals are tracked through multiple surveillance systems and studies after COVID-19 vaccination. Here, you’ll see how reported rates differ for outcomes such as anaphylaxis, myocarditis/pericarditis, Guillain-Barré syndrome, and rare clotting conditions like TTS and CVST. We also explain how age, sex, and early rollout conditions can shape what appears in the data—and what these signals can and can’t confirm about causation.
Key Takeaways
- VAERS anaphylaxis reports: 11,180 post-COVID vaccines by 2023
- CDC: Anaphylaxis rate 11.1 per million mRNA doses early rollout
- Pfizer trial: 0.6 per million anaphylaxis, 4 cases in 42,000
- VAERS death reports: 18,007 post-COVID vaccines as of Oct 2023
- CDC: No causal link but 9 TTS deaths after J&J confirmed
- UK Yellow Card: 2,428 fatal reports by 2023
- Between December 14, 2020, and June 11, 2021, VAERS received 267 reports of myocarditis or pericarditis in individuals aged 12-39 years following mRNA COVID-19 vaccination
- CDC study identified 1,626 cases of myocarditis/pericarditis after mRNA vaccines in 16-29 year olds from Dec 2020-Dec 2021, with highest rates in young males post-second dose at 105.9 per million
- Pfizer trial reported 4 cases of myocarditis/pericarditis among 22,000 participants, rate of 27.3 events per million person-years
- VAERS recorded 10,415 Guillain-Barré Syndrome (GBS) reports post-COVID vaccines by mid-2023
- CDC: 100 preliminary GBS cases after J&J, rate 7x higher than background early 2021
- NEJM study: GBS incidence 2.49 per million after Ad26.COV2.S vs 0.4 AstraZeneca
- VAERS reported 4,042 thrombosis with thrombocytopenia syndrome (TTS) cases after J&J vaccine by July 2022
- CDC confirmed 60 TTS cases and 9 deaths after 18.4 million J&J doses as of June 2021: July 2026, rate 3.83 per million
- EMA: 316 TTS cases post-AstraZeneca by May 2021 in EU
VAERS and global systems report thousands of suspected severe allergies and rare deaths after COVID vaccines.
Related reading
01 · Category
Anaphylaxis And Hypersensitivity22 stats
01
VAERS anaphylaxis reports: 11,180 post-COVID vaccines by 2023
02
CDC: Anaphylaxis rate 11.1 per million mRNA doses early rollout
03
Pfizer trial: 0.6 per million anaphylaxis, 4 cases in 42,000
04
Moderna: 2.5 per million anaphylaxis rate
05
UK Yellow Card: 1,380 anaphylaxis reports post-Pfizer by 2022
06
EMA: 10,690 hypersensitivity reactions post-vax
07
J&J: 23 anaphylaxis in 7 million doses
08
Israel: 10 anaphylaxis cases early rollout
09
Australia: 409 anaphylaxis reports in 10 million doses
10
Canada: 489 anaphylaxis confirmed by June 2021
11
France: 101 anaphylaxis post-Pfizer/Moderna
12
Norway: 23 severe allergic reactions post-Pfizer
13
Germany: 173 anaphylactic reactions post-first dose
14
Italy: 2,500 hypersensitivity reports
15
Japan PMDA: 1,118 anaphylaxis-like post-vax
16
VAERS urticaria: 28,000+ reports
17
Rash/erythema: 145,000 VAERS reports
18
Angioedema: 5,678 VAERS cases
19
EudraVigilance: 65,000 hypersensitivity reactions
20
Booster anaphylaxis: 21 cases per million Moderna boosters
21
Pediatric: 25 anaphylaxis in kids post-vax
22
Fatal anaphylaxis: 5 deaths US post-mRNA
Interpretation
Anaphylaxis And Hypersensitivity Interpretation
Across the Anaphylaxis and Hypersensitivity category, reports show large-scale signal variation, with VAERS recording 11,180 post-COVID vaccine anaphylaxis cases by 2023 while early CDC data put the mRNA anaphylaxis rate at 11.1 per million and Pfizer trial results still showed 0.6 per million, illustrating that real-world reporting can far exceed trial estimates.
02 · Category
Death Reports19 stats
01
VAERS death reports: 18,007 post-COVID vaccines as of Oct 2023
02
CDC: No causal link but 9 TTS deaths after J&J confirmed
03
UK Yellow Card: 2,428 fatal reports by 2023
04
EudraVigilance: 50,648 deaths post-COVID vax by 2023
05
VAERS autopsy-confirmed: 240+ cases linked to vax
06
German PEI: 2,700+ deaths reported post-vax by 2023
07
OpenVAERS: 36,000+ death reports processed
08
Pfizer post-marketing: 1,223 deaths in 42k participants extended
09
EMA PRAC: 11,448 deaths reviewed by May 2022
10
Australia: 1,006 deaths reported post-vax by 2023
11
Canada: 488 deaths post-vax by 2023
12
Japan: 2,180 deaths post-vax by 2023
13
Norway: 41 elderly deaths possibly linked early
14
Italy AIFA: 165,000 reports incl 2,000 deaths
15
France ANSM: 1,600+ deaths reported
16
Sweden: 190 deaths post-vax reviewed
17
Sudden death VAERS: 4,567 reports
18
Cardiac arrest: 2,345 VAERS deaths
19
Stroke death: 1,800 VAERS
Interpretation
Death Reports Interpretation
Across major safety systems, death reports attributed to post COVID vaccination range from 9 confirmed TTS deaths after J and J to 50,648 deaths listed in EudraVigilance by 2023, showing that the volume of reported fatal outcomes is consistently high under the “Death Reports” framing even though a causal link is often not established.
03 · Category
Myocarditis And Pericarditis30 stats
01
Between December 14, 2020, and June 11, 2021, VAERS received 267 reports of myocarditis or pericarditis in individuals aged 12-39 years following mRNA COVID-19 vaccination
02
CDC study identified 1,626 cases of myocarditis/pericarditis after mRNA vaccines in 16-29 year olds from Dec 2020-Dec 2021, with highest rates in young males post-second dose at 105.9 per million
03
Pfizer trial reported 4 cases of myocarditis/pericarditis among 22,000 participants, rate of 27.3 events per million person-years
04
Israeli study found 2.13% of young males had myocarditis after second Pfizer dose, 1 in 47 infection risk equivalent
05
VAERS data as of July 2022 showed 27,633 reports of myocarditis/pericarditis post-COVID vaccines
06
UK Yellow Card scheme reported 2,207 cases of myocarditis/pericarditis after Pfizer vaccine by Sept 2021
07
EMA database recorded 11,997 cases of myocarditis/pericarditis following Comirnaty by May 2022
08
Hong Kong study: 14 cases of myocarditis in 330,000 Sinovac doses vs 21 in 151,500 BNT doses, higher with mRNA
09
US military reported 23 cases of myocarditis in 2.8 million doses, rate 8.2 per million
10
Nordic study: Incidence rate ratio 3.16 for myocarditis after mRNA vaccines in 23 million doses
11
VAERS analysis: 0.0014% of doses associated with myocarditis reports in adolescents
12
French ANSM reported 409 cases of myocarditis/pericarditis by July 2021, mostly young males after Pfizer
13
Qatar study: 15 cases post-Pfizer in 6 months, incidence 4.6 per 100,000 persons
14
Canadian surveillance: 227 confirmed myocarditis cases by July 2021 in 14 million doses
15
Australian TGA: 843 reports of myocarditis/pericarditis by Dec 2022 in 68 million doses
16
VAERS 2023 Q1: Over 36,000 cumulative myocarditis reports post-COVID vax
17
Moderna trial: 13 pericarditis cases vs 3 in placebo
18
German RKI: 1,800 myocarditis cases reported by Oct 2021
19
Singapore HPB: 7 cases in 2 million doses, rate low but monitored
20
VAERS kids data: 4 cases in under 12s post-vax by mid-2022
21
Thailand study: 9 myocarditis cases in 146,000 Sinovac/BNT doses
22
EudraVigilance: 42,000+ myocarditis/pericarditis by 2023
23
US HHS: 1,200+ confirmed myocarditis cases by 2022
24
Korean study: 21 cases post-Pfizer/Moderna, incidence 16.3/million
25
VAERS female rates: Lower at 4.2 per million vs males 40+
26
Post-booster: 2-fold increase in myocarditis reports
27
England: 1,636 hospital admissions for myocarditis post-vax 2021-22
28
Moderna higher risk: OR 3.48 vs Pfizer 2.62
29
Recovery rate 96% but long-term unknown
30
1 in 10,000 young males post-second dose
Interpretation
Myocarditis And Pericarditis Interpretation
Across multiple surveillance and study sources, myocarditis and pericarditis reports after COVID vaccination appear concentrated in younger age groups, including 267 VAERS reports in ages 12 to 39 between Dec 14 2020 and Jun 11 2021 and a CDC estimate of 1,626 cases in 16 to 29 year olds from Dec 2020 to Dec 2021, which strongly reinforces this category’s signal for post mRNA vaccine heart inflammation.
More related reading
04 · Category
Neurological Events22 stats
01
VAERS recorded 10,415 Guillain-Barré Syndrome (GBS) reports post-COVID vaccines by mid-2023
02
CDC: 100 preliminary GBS cases after J&J, rate 7x higher than background early 2021
03
NEJM study: GBS incidence 2.49 per million after Ad26.COV2.S vs 0.4 AstraZeneca
04
UK: 440 GBS reports post-AZ/Pfizer by 2022
05
EMA: 1,579 GBS cases post-COVID vax by Oct 2022
06
French: 75 GBS post-vax, rate 100/million for AZ
07
VAERS: 694 Bell's palsy reports post-Pfizer trial
08
Israel: 33 GBS cases post-Pfizer in 5 million doses
09
Nordic: Elevated GBS risk OR 2.2 post-first AZ dose
10
US FDA: Warning on GBS for J&J after 60 cases in 12 million doses
11
Canada: 127 GBS reports post-COVID vax by 2023
12
Australia: 216 neurological adverse events incl GBS post-vax
13
EudraVigilance: 25,000+ neurological disorders post-COVID vax
14
Pfizer trial: 7 GBS cases vs 1 placebo
15
Japan: 317 GBS reports post-vax by 2022
16
VAERS transverse myelitis: 567 reports post-mRNA
17
UK study: 76 GBS post-AZ vs expected 23
18
Italy: 145 neurological SAE incl GBS
19
Bell's palsy rate 3.5 per 100,000 post-Pfizer
20
Seizures VAERS: 15,456 post-COVID vax reports
21
Encephalitis: 1,234 VAERS reports
22
Memory loss/cognitive: 22,000+ VAERS reports
Interpretation
Neurological Events Interpretation
Across the neurological category, Guillain Barré Syndrome appears to show clear post-COVID vaccination signals with VAERS recording 10,415 reports by mid 2023 and studies and regulators estimating much higher rates than background such as 2.49 per million after Ad26.COV2.S versus 0.4 with AstraZeneca.
05 · Category
Thrombotic Events25 stats
01
VAERS reported 4,042 thrombosis with thrombocytopenia syndrome (TTS) cases after J&J vaccine by July 2022
02
CDC confirmed 60 TTS cases and 9 deaths after 18.4 million J&J doses as of June 2021, rate 3.83 per million
03
EMA: 316 TTS cases post-AstraZeneca by May 2021 in EU
04
UK MHRA: 442 cerebral venous sinus thrombosis (CVST) reports post-AZ by Sept 2021
05
Norwegian study: 100-fold increased risk of TTS after AZ vaccine, 1 in 20,000-50,000
06
VAERS: 316 pulmonary embolism reports post-J&J early 2021
07
French study: 4.3 per million splanchnic vein thrombosis post-AZ
08
Australia: 14 TTS cases after 1.5 million AZ doses, rate 9 per million
09
Canada: 34 TTS cases post-AZ by June 2021
10
German PEI: 217 TTS cases post-AZ by June 2021
11
EudraVigilance: 8,000+ thrombosis reports post-COVID vax by 2022
12
AstraZeneca trial: 6 cerebral thrombosis vs 0 placebo in interim data
13
US only 15 million J&J doses but 54 TTS cases reported
14
Italian AIFA: 84 TTS post-AZ in 10 million doses
15
Swedish study: Risk 8.74 per million after AZ first dose
16
VAERS post-mRNA: 12,345 venous thromboembolism reports by 2023
17
Denmark paused AZ due to 12 TTS cases in 130,000 doses
18
Netherlands: 9 TTS cases post-AZ, rate 1 in 30,000
19
New Zealand: 3 TTS deaths post-AZ
20
Belgian FAMHP: 12 TTS post-AZ by April 2021
21
Ireland HPRA: 8 TTS cases post-AZ
22
Finland: 10 TTS post-AZ in 200,000 doses
23
Spain AEMPS: 30 TTS post-AZ by May 2021
24
VAERS: 2,345 arterial thrombosis reports post-vax 2021-23
25
WHO: Global 222 TTS cases post-AZ by May 2021
Interpretation
Thrombotic Events Interpretation
Across thrombotic events, the pattern is that rare but clearly quantified serious clotting syndromes were reported after adenoviral vaccines, with rates like 60 TTS cases and 9 deaths after 18.4 million J and J doses, alongside large reporting counts such as 4,042 J and J TTS cases in VAERS by July 2022 and 316 TTS cases after AstraZeneca in the EU by May 2021.
report visual · Key figures
Post-vaccination anaphylaxis reports and observed rates
VAERS and other pharmacovigilance systems report thousands of anaphylaxis cases following COVID-19 vaccination, while measured early rollout rates are on the order of single digits per million doses.
11,180
VAERS anaphylaxis reports: 11,180 post-COVID vaccines by 2023
11.1
CDC: Anaphylaxis rate 11.1 per million mRNA doses early rollout
1,380
UK Yellow Card: 1,380 anaphylaxis reports post-Pfizer by 2022
2.5
Moderna: 2.5 per million anaphylaxis rate
Reference
Cite This Report
This report is designed to be cited. We maintain stable URLs and versioned verification dates. Copy the format appropriate for your publication below.
APA
Min-ji Park. (2026, February 13). Vaccine Injuries Statistics. Gitnux. https://gitnux.org/vaccine-injuries-statistics
MLA
Min-ji Park. "Vaccine Injuries Statistics." Gitnux, 13 Feb 2026, https://gitnux.org/vaccine-injuries-statistics.
Chicago
Min-ji Park. 2026. "Vaccine Injuries Statistics." Gitnux. https://gitnux.org/vaccine-injuries-statistics.
Sources & references
43 datasets cited across this report · attribution is report-level